Prescribing biosimilars

Jeffrey K Aronson^{1

2}, Ben Goldacre³, Robin E Ferner^{2

4}

Affiliations

¹ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK jeffrey.aronson@phc.ox.ac.uk.
² West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.
³ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK.
⁴ Institute of Clinical Sciences, University of Birmingham, UK.

Editorial

Jeffrey K Aronson et al. BMJ. 2018.

. 2018 Jul 24:362:k3141.

doi: 10.1136/bmj.k3141.

Jeffrey K Aronson^{1

2}, Ben Goldacre³, Robin E Ferner^{2

4}

¹ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK jeffrey.aronson@phc.ox.ac.uk.
² West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.
³ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK.
⁴ Institute of Clinical Sciences, University of Birmingham, UK.

No abstract available

Conflict of interest statement

Competing interests: We have read and understood BMJ policy on declaration of interests and have no relevant interests to declare.